30
Participants
Start Date
October 1, 2020
Primary Completion Date
October 11, 2022
Study Completion Date
October 11, 2022
TACE combined with sorafenib and tislelizumab
Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
The 2nd Affiliated Hospital of Guangzhou Medical University, Guangzhou
the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
Second Affiliated Hospital of Guangzhou Medical University
OTHER